Literature DB >> 19383787

Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity.

Yong-Jie Zhang1, Ya-Fei Xu, Casey Cook, Tania F Gendron, Paul Roettges, Christopher D Link, Wen-Lang Lin, Jimei Tong, Monica Castanedes-Casey, Peter Ash, Jennifer Gass, Vijayaraghavan Rangachari, Emanuele Buratti, Francisco Baralle, Todd E Golde, Dennis W Dickson, Leonard Petrucelli.   

Abstract

Inclusions of TAR DNA-binding protein-43 (TDP-43), a nuclear protein that regulates transcription and RNA splicing, are the defining histopathological feature of frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-Us) and sporadic and familial forms of amyotrophic lateral sclerosis (ALS). In ALS and FTLD-U, aggregated, ubiquitinated, and N-terminally truncated TDP-43 can be isolated from brain tissue rich in neuronal and glial cytoplasmic inclusions. The loss of TDP-43 function resulting from inappropriate cleavage, translocation from the nucleus, or its sequestration into inclusions could play important roles in neurodegeneration. However, it is not known whether TDP-43 fragments directly mediate toxicity and, more specifically, whether their abnormal aggregation is a cause or consequence of pathogenesis. We report that the ectopic expression of a approximately 25-kDa TDP-43 fragment corresponding to the C-terminal truncation product of caspase-cleaved TDP-43 leads to the formation of toxic, insoluble, and ubiquitin- and phospho-positive cytoplasmic inclusions within cells. The 25-kDa C-terminal fragment is more prone to phosphorylation at S409/S410 than full-length TDP-43, but phosphorylation at these sites is not required for inclusion formation or toxicity. Although this fragment shows no biological activity, its exogenous expression neither inhibits the function nor causes the sequestration of full-length nuclear TDP-43, suggesting that the 25-kDa fragment can induce cell death through a toxic gain-of-function. Finally, by generating a conformation-dependent antibody that detects C-terminal fragments, we show that this toxic cleavage product is specific for pathologic inclusions in human TDP-43 proteinopathies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19383787      PMCID: PMC2671323          DOI: 10.1073/pnas.0900688106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

Review 1.  hnRNP complexes: composition, structure, and function.

Authors:  A M Krecic; M S Swanson
Journal:  Curr Opin Cell Biol       Date:  1999-06       Impact factor: 8.382

Review 2.  Messenger-RNA-binding proteins and the messages they carry.

Authors:  Gideon Dreyfuss; V Narry Kim; Naoyuki Kataoka
Journal:  Nat Rev Mol Cell Biol       Date:  2002-03       Impact factor: 94.444

3.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

4.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease.

Authors:  A Goate; M C Chartier-Harlin; M Mullan; J Brown; F Crawford; L Fidani; L Giuffra; A Haynes; N Irving; L James
Journal:  Nature       Date:  1991-02-21       Impact factor: 49.962

5.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Tetsuaki Arai; Masato Hasegawa; Haruhiko Akiyama; Kenji Ikeda; Takashi Nonaka; Hiroshi Mori; David Mann; Kuniaki Tsuchiya; Mari Yoshida; Yoshio Hashizume; Tatsuro Oda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-30       Impact factor: 3.575

6.  Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.

Authors:  M Hutton; C L Lendon; P Rizzu; M Baker; S Froelich; H Houlden; S Pickering-Brown; S Chakraverty; A Isaacs; A Grover; J Hackett; J Adamson; S Lincoln; D Dickson; P Davies; R C Petersen; M Stevens; E de Graaff; E Wauters; J van Baren; M Hillebrand; M Joosse; J M Kwon; P Nowotny; L K Che; J Norton; J C Morris; L A Reed; J Trojanowski; H Basun; L Lannfelt; M Neystat; S Fahn; F Dark; T Tannenberg; P R Dodd; N Hayward; J B Kwok; P R Schofield; A Andreadis; J Snowden; D Craufurd; D Neary; F Owen; B A Oostra; J Hardy; A Goate; J van Swieten; D Mann; T Lynch; P Heutink
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

7.  Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9.

Authors:  E Buratti; F E Baralle
Journal:  J Biol Chem       Date:  2001-07-24       Impact factor: 5.157

8.  TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: an important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing.

Authors:  Emanuele Buratti; Antonia Brindisi; Maurizio Giombi; Sergio Tisminetzky; Youhna M Ayala; Francisco E Baralle
Journal:  J Biol Chem       Date:  2005-09-12       Impact factor: 5.157

9.  Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element.

Authors:  F Pagani; E Buratti; C Stuani; M Romano; E Zuccato; M Niksic; L Giglio; D Faraguna; F E Baralle
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

10.  Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43.

Authors:  Yong-Jie Zhang; Ya-fei Xu; Chad A Dickey; Emanuele Buratti; Francisco Baralle; Rachel Bailey; Stuart Pickering-Brown; Dennis Dickson; Leonard Petrucelli
Journal:  J Neurosci       Date:  2007-09-26       Impact factor: 6.167

View more
  279 in total

1.  Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A.

Authors:  Naoya Aoki; Melissa E Murray; Kotaro Ogaki; Shinsuke Fujioka; Nicola J Rutherford; Rosa Rademakers; Owen A Ross; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-11-04       Impact factor: 17.088

2.  Neurotoxic effects of TDP-43 overexpression in C. elegans.

Authors:  Peter E A Ash; Yong-Jie Zhang; Christine M Roberts; Tassa Saldi; Harald Hutter; Emanuele Buratti; Leonard Petrucelli; Christopher D Link
Journal:  Hum Mol Genet       Date:  2010-06-08       Impact factor: 6.150

3.  Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models.

Authors:  Alexander M Herman; Preeti J Khandelwal; G William Rebeck; Charbel E-H Moussa
Journal:  Exp Neurol       Date:  2012-02-28       Impact factor: 5.330

Review 4.  Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurosci       Date:  2011-11-30       Impact factor: 34.870

5.  The self-interaction of native TDP-43 C terminus inhibits its degradation and contributes to early proteinopathies.

Authors:  I-Fan Wang; Hsiang-Yu Chang; Shin-Chen Hou; Gunn-Guang Liou; Tzong-Der Way; C-K James Shen
Journal:  Nat Commun       Date:  2012-04-03       Impact factor: 14.919

6.  Wnt signaling as a potential therapeutic target for frontotemporal dementia.

Authors:  Zeljka Korade; Károly Mirnics
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

Review 7.  TAR DNA-binding protein 43 in neurodegenerative disease.

Authors:  Alice S Chen-Plotkin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Nat Rev Neurol       Date:  2010-03-16       Impact factor: 42.937

8.  Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains.

Authors:  Keith A Josephs; Melissa E Murray; Nirubol Tosakulwong; Stephen D Weigand; Amanda M Serie; Ralph B Perkerson; Billie J Matchett; Clifford R Jack; David S Knopman; Ronald C Petersen; Joseph E Parisi; Leonard Petrucelli; Matthew Baker; Rosa Rademakers; Jennifer L Whitwell; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2019-01-02       Impact factor: 17.088

9.  A truncating SOD1 mutation, p.Gly141X, is associated with clinical and pathologic heterogeneity, including frontotemporal lobar degeneration.

Authors:  Masataka Nakamura; Kevin F Bieniek; Wen-Lang Lin; Neill R Graff-Radford; Melissa E Murray; Monica Castanedes-Casey; Pamela Desaro; Matthew C Baker; Nicola J Rutherford; Janice Robertson; Rosa Rademakers; Dennis W Dickson; Kevin B Boylan
Journal:  Acta Neuropathol       Date:  2015-04-28       Impact factor: 17.088

Review 10.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.